What does this research mean for the field?

Long-term responders (PFS >18 months) to first-line anti-HER2 therapy in HER2-positive metastatic breast cancer exhibit evolving treatment patterns and outcomes. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

This analysis aimed to investigate long-term outcomes for patients with HER2-positive metastatic breast cancer receiving standard first-line therapy.

February 19, 2026Clinical Cancer Research

Abstract PS5-02-14: "longterm" - long-term response (18 months) in metastatic her2-positive breast cancer: a retrospective analysis of patients diagnosed between 2010 and 2020 in the german bngo network

View Full Paper

Ask AI

Bookmark

Authors

GHG. E. HeinrichGynecologic Oncology Group

Discussion

Member takes

Implication

Retrospective analysis reports long-term outcomes in HER2-positive metastatic breast cancer, suggesting effective treatment strategies.

Key Points

This analysis aimed to investigate long-term outcomes for patients with HER2-positive metastatic breast cancer receiving standard first-line therapy.
Multicenter, retrospective analysis of patients diagnosed between 2010 and 2020.
Inclusion of patients with HER2 IHC 3+ and/or ISH-positive disease.
Data collected from electronic case report forms and site documentation.
95 out of 111 patients met eligibility criteria.
Median age at diagnosis was 61.1 years; 58.9% had prior early-stage HER2+ disease.
74.7% received chemotherapy with anti-HER2 therapy; 69.5% remained under therapy at follow-up.

Cite This Study

G. E. Heinrich (2026) studied this question.

synapsesocial.com/papers/6996a8d4ecb39a600b3efe92 https://doi.org/10.1158/1557-3265.sabcs25-ps5-02-14

View Full Paper

Ask AI

Bookmark

Abstract PS5-02-14: "longterm" - long-term response (18 months) in metastatic her2-positive breast cancer: a retrospective analysis of patients diagnosed between 2010 and 2020 in the german bngo network

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS5-02-14: "longterm" - long-term response (18 months) in metastatic her2-positive breast cancer: a retrospective analysis of patients diagnosed between 2010 and 2020 in the german bngo network

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider